Home
The treatment landscape for inflammatory bowel disease (IBD) is evolving rapidly. Novel pharmacologic agents with different mechanisms of action are advancing the management of both ulcerative colitis and Crohn’s disease. Clinicians need education to stay abreast of the la test developments in IBD treatment, including positioning of new agents in treatment plans, efficacy and safety data, setting treatment goals, monitoring response, and adjusting treatment in patients who relapse. Join us for a fun,